A royalty is a contractual right to receive a stream of income based on the use or exploitation of an asset — a song, a drug, a mineral deposit — without bearing the operational costs or risks of running the underlying business. Royalty investing has attracted significant institutional and HNW interest over the past decade, driven by its combination of income characteristics, inflation linkage in some segments, and low correlation to financial market cycles.
Capital is at risk. Royalty streams can decline, terminate or be subject to legal dispute. This guide is for information only and does not constitute regulated investment advice. Past performance is not reliable guidance for future results.
Why Royalty Streams Are Attractive
The appeal of royalty investing rests on three characteristics:
Passive income without operational exposure. The royalty owner receives income based on production, sales or use without funding the costs of drilling, manufacturing or marketing. Operating leverage risk sits with the operator; the royalty owner has a senior, revenue-level claim.
Inflation characteristics. Many royalty streams are linked to commodity prices or top-line revenues rather than fixed nominal amounts. A gold royalty, for example, rises in value as the gold price rises. Pharmaceutical royalties track drug sales, which typically grow with volume and pricing.
Duration and diversification. A music royalty catalogue may generate cash flows for 70+ years after the death of the composer. A pharmaceutical royalty typically expires when the patent does. Understanding duration is critical to valuation.
Music Royalties
Music royalties derive from two principal sources:
Publishing rights (also called composition rights) — the underlying song, owned by the songwriter or their publishing company. Royalties are generated from public performance (radio, live events, streaming services), synchronisation (use in film, TV, advertising) and mechanical reproduction (physical sales, digital downloads, streaming mechanicals).
Master recording rights — the specific recorded performance of a song, typically owned by record labels. These generate recording royalties from streaming and physical sales.
The investment case for music royalties has been transformed by streaming. Platforms such as Spotify, Apple Music and YouTube have created a predictable, growing, global royalty distribution system. Total streaming royalty payments have grown at double-digit rates annually in recent years as subscriber numbers expand and per-stream rates evolve.
Hipgnosis Songs Fund — formerly listed on the London Stock Exchange — pursued an aggressive catalogue acquisition strategy, acquiring interests in songs by Shakira, Justin Timberlake, Blondie and many others. The fund's travails are instructive: disputes over valuations (challenged by an independent valuer in 2023), concerns about acquisition pricing, a difficult refinancing environment in the rising rate period 2022–23, and ultimately a contested takeover bid illustrate the risks in the sector. The fund's discount to net asset value became material, highlighting the gap between the long-duration theoretical values of music catalogues and investor willingness to hold illiquid assets at those valuations in a higher rate environment.
Round Hill Music Royalty Fund faced similar pressures and was eventually wound up following a strategic review.
These experiences do not invalidate the music royalty investment thesis but do illustrate duration risk in a higher-rate environment — long-duration assets are more sensitive to discount rate movements than short-duration ones — and governance risk in externally managed listed vehicles where manager incentives may not fully align with shareholders.
Private funds — including those managed by KKR (through Round Hill Music's institutional track), Shamrock Capital and independent music-focused managers — continue to attract institutional capital at valuations that are privately negotiated rather than publicly quoted.
Pharmaceutical Royalties
Pharmaceutical royalties arise from licensing agreements: a drug developer licenses its intellectual property to a pharmaceutical company in exchange for royalty payments on net sales of the resulting drug, typically for the life of the relevant patents.
The pharmaceutical royalty market has been institutionalised by dedicated royalty companies, most notably Royalty Pharma (Nasdaq: RPRX), which is the largest acquirer of biopharmaceutical royalties. Royalty Pharma holds royalties on drugs including cystic fibrosis therapies (Trikafta, Orkambi — developed by Vertex Pharmaceuticals), HIV treatments, oncology drugs and immunology products.
Return characteristics. Royalty Pharma and similar vehicles derive returns from:
- Drug sales volumes and pricing (subject to payer pressure, biosimilar competition and patent expiry)
- Diversification across multiple drugs and therapeutic areas reduces single-drug risk
- New royalty acquisitions at attractive implied valuations
Patent cliff risk. When the relevant patents expire — typically 20 years from filing, with some extensions available — the royalty income ceases unless the product is replaced by a next-generation successor. Portfolio management involves constantly replenishing expiring royalties with new acquisitions.
Drug development risk. Some royalty agreements include milestone payments contingent on clinical trial outcomes. Royalty Pharma's Biohaven migraine drug (rimegepant) is an example of a royalty on a drug still in development at the time of acquisition — a higher-risk but potentially higher-returning structure.
Smaller, private pharmaceutical royalty funds also operate in this space, acquiring royalties on approved and late-stage drugs, often at better valuations than the publicly listed Royalty Pharma given reduced competition.
Natural Resource Royalties
Natural resource royalties are payments made by mining or energy companies to the owners of mineral rights based on the volume or value of resources extracted. Royalty structures dominate in the Canadian and US mining sector.
Types of royalty:
- Net smelter return (NSR): a percentage of the revenue received by the operator from the sale of extracted minerals, net of transportation and processing costs. The most common form.
- Net profit interest (NPI): a percentage of profits, meaning the royalty owner shares in cost risk. Less favourable for investors.
- Gross overriding royalty (GOR): similar to NSR, used in oil and gas contexts.
- Streaming agreements: technically distinct from royalties, streams involve an upfront payment in exchange for the right to purchase gold, silver or copper at a fixed, below-market price for a defined or perpetual term. Franco-Nevada, Royal Gold (Nasdaq: RGLD) and Wheaton Precious Metals (NYSE: WPM) are the leading streaming and royalty companies.
Investment case. Resource royalty companies provide:
- Leverage to commodity prices without operating risk (they bear no mining costs)
- Diversification across many projects and geographies in a single vehicle
- Inflation linkage through commodity price linkage
- Senior claim on revenue, unlike equity in a mining company
Risks. Mine development risk — the mine underlying the royalty may not reach production, or production may be lower than expected. Counterparty risk — the operator must remain financially viable. Commodity price risk — while inflation-linked, a sustained commodity bear market reduces royalty income. Political risk — resource royalties in emerging market jurisdictions carry sovereign and regulatory risk.
Franco-Nevada (NYSE and TSX: FNV), Royal Gold and Wheaton Precious Metals are accessible to individual investors via standard equity brokerage and are the most liquid way to access resource royalties. Unlisted royalty portfolios targeting specific minerals — copper, lithium, cobalt — are available to institutional and sophisticated investors through private fund structures.
Comparing Royalty Segments
| Characteristic | Music Royalties | Pharma Royalties | Resource Royalties |
|---|---|---|---|
| Duration | 70+ years (post-death) | Patent life (15–20 years) | Mine life (variable) |
| Inflation linkage | Moderate (streaming rates) | Moderate (drug pricing) | Strong (commodity prices) |
| Correlation to equities | Low | Moderate | Moderate-high |
| Liquidity | Low (private) / Medium (listed) | Medium (Royalty Pharma) | High (listed companies) |
| Key risk | Discount rate / streaming economics | Patent cliff / clinical failure | Commodity price / mine risk |
Access Routes for UK and International HNW Investors
Listed equity vehicles are the most accessible: Royalty Pharma, Franco-Nevada, Wheaton Precious Metals, Royal Gold are exchange-listed and available through standard brokerages. Note that as equity instruments, they carry equity market correlation alongside underlying royalty dynamics.
Closed-ended listed funds — though the experience of Hipgnosis and Round Hill warns investors to scrutinise valuation methodology, governance, leverage and manager incentives carefully before committing capital.
Private royalty funds — specialist managers including Music Royalties Inc, Sony Music Publishing's royalty vehicles and pharma royalty specialists operate closed-ended private funds with minimum commitments typically starting at $500,000–$1 million.
Direct acquisition — very large family offices and specialist investors occasionally acquire individual music catalogues or pharmaceutical royalties directly, but this requires deep expertise, legal resources and scale.
How Global Investments Can Help
Royalty investing rewards specialist knowledge and careful valuation discipline. Our advisory team can help you identify appropriate access routes across the royalty spectrum — listed vehicles, private funds or direct structures — assess the risk-return profile relative to your existing alternatives allocation, and evaluate manager track records and governance quality. We can also stress-test royalty positions against interest rate, patent expiry and commodity price scenarios.
Contact us to discuss royalty investing and how it might complement your portfolio.
This guide is for general information only and does not constitute financial advice or a personal recommendation. The value of investments can fall as well as rise and you may get back less than you invest. Past performance is not a guide to future returns. Tax rules, investment regulations, and the availability of specific investment vehicles change — always verify current rules and seek advice from a qualified independent financial adviser before making any investment decisions.